- 2013
-
News in brief - 27.02.2013
NanoAthero: using nanomedicine to treat cardiovascular diseases
Sixteen partners from 10 European countries got together to create the “Nanomedicine for Atherosclerosis” consortium. Its aim is to study and develop the clinical feasibility of nanomedicine for targeted diagnosis and treatment of atherosclerosis. Coordinated by Inserm, the project has just obtaining funding amounting to 10 million euros over five years from the European Commission. […]
-
What's on? - 27.02.2013
28 February: international rare diseases day
Rare diseases currently affect fewer than one in 2000 people. There are 8,000 such diseases in the world, and five new ones are identified every month. They are generally genetic conditions, but also include auto-immune diseases, infectious diseases, cancers, etc. The Sixth International Day of Rare Diseases was held on Thursday 28 February in more […]
-
Press releases - 27.02.2013
André Syrota reappointed as Inserm Chairman and CEO
André Syrota has been reappointed by the French government as Chairman and CEO of the National Institute of Health and Medical Research (Inserm), on the recommendation of the Minister for Higher Education and Research, Geneviève Fioraso.
-
Press releases - 26.02.2013
Treatment with HDL cholesterol to aid thrombolysis
Research performed by the Neurology Department and Stroke Reception and Treatment Unit at the Bichat Hospital (AP-HP/ Paris University Diderot) and the associated INSERM Unit 698 (Prof. Amarenco, Dr Olivier Meilhac) has highlighted the benefits of good cholesterol in reducing bleeding complications in the only treatment available for embolic stroke. The results of this experiment, performed on the rat, have just been published in Stroke .
-
What's on? - 26.02.2013
Study of the consumption of food supplements
Very little information is currently available in France about the consumption of food supplements and the associated behavioural factors, in particular in population groups such as smokers for whom, according to researchers, the taking of certain supplements could represent an increased risk in relation to certain diseases. The relative proportion of people who are self-medicating […]
-
Press releases - 26.02.2013
By the sixth month of pregnancy, the human brain is capable of processing speech
The immature brain of a premature infant is capable, at the age of three months pre-term, of distinguishing syllables uttered by male and female voices. These results obtained by INSERM researchers at the University of Picardy Jules Verne and the CEA’s NeuroSpin Imaging Centre, were published in the PNAS journal dated 25 February 2013. They highlight the very early sophisticated organisation of the regions of the brain involved in language-processing and social communication in humans.
-
What's on? - 21.02.2013
Artificial eye: promising results
Researchers at Tübingen University in Germany have succeeded in partially restoring the eyesight to six patients (out of nine treated) who were suffering from retinitis pigmentosa thanks to a prosthesis known as Retina. This genetic condition involves a progressive reduction in sight until the patient becomes totally blind, due to a loss of photoreceptors in […]
-
Press releases - 21.02.2013
COMBACTE: A new step in the fight against resistance to antibiotics
Antimicrobial resistance represents is a growing problem in public health due the increasing rarity of antibiotics capable of combating resistant bacteria. The COMBACTE project, that has just obtained 195 million euros worth of finance from the Innovative Medicines Initiative (IMI), aims to work to develop new antibiotics and introduce a successful clinical trials platform combining private and public research.
-
Press releases - 21.02.2013
L’Inserm et l’Université Toulouse III – Paul Sabatier renouvellent leur partenariat
L’Inserm et l’Université Toulouse III – Paul Sabatier renouvellent leur partenariat en matière de recherche, de valorisation et de transfert de connaissances en sciences du vivant.
-
Press releases - 20.02.2013
Obesity and insulin resistance: the lipolysis route
Liver and skeletal muscle resistance to the action of insulin is an early sign of the development of Type 2 Diabetes. The INSERM team at the “Obesity Research Laboratory ” in the Institut des Maladies Métaboliques and Cardiovasculaires (INSERM / Université Toulouse III – Paul Sabatier), headed by Dominique Langin, has shown through results published this week, that there is an association between lipolysis (mobilisation of fat in response to the body’s need for energy) and insulin sensitivity in humans.